Suppr超能文献

表面活性蛋白 A 在囊性纤维化中的作用:超分子结构与肺部结局。

Surfactant protein a in cystic fibrosis: supratrimeric structure and pulmonary outcome.

机构信息

Dr. von Haunersches Kinderspital, University of Munich, Munich, Germany.

出版信息

PLoS One. 2012;7(12):e51050. doi: 10.1371/journal.pone.0051050. Epub 2012 Dec 7.

Abstract

BACKGROUND

The state of oligomerization of surfactant associated protein-A (SP-A) monomers differs between individuals. This likely affects SP-A's functional properties and could thereby influence clinical status in patients with lung diseases. In this study we focus on SP-A structure in cystic fibrosis (CF) compared to both healthy subjects and disease controls.

METHODS

SP-A composition and function were assessed in both bronchoalveolar lavage (BAL) fluid and serum of 46 CF patients with mild disease, 25 patients with chronic bronchitis and 22 healthy subjects by gel chromatography and a functional agglutination assay. Relation of SP-A agglutination ability to disease severity of the subjects was explored.

RESULTS

SP-A was present in seven major oligomeric forms with the majority of SP-A being structurally organized as complex oligomeric forms. More complex oligomeric forms were associated with better SP-A function with regard to its agglutination ability. These forms were more frequently observed in BAL than in serum, but there were no differences between disease groups. In CF patients, more complex forms of SP-A were associated with better lung function.

CONCLUSIONS

Organizational structure of SP-A affects its functional activity and is linked to disease severity in CF.

摘要

背景

表面活性剂相关蛋白 A(SP-A)单体的聚集状态在个体之间存在差异。这可能会影响 SP-A 的功能特性,并因此影响肺部疾病患者的临床状况。在这项研究中,我们重点研究了囊性纤维化(CF)中 SP-A 的结构,将其与健康受试者和疾病对照组进行了比较。

方法

通过凝胶色谱法和功能凝集试验,评估了 46 例轻度 CF 患者、25 例慢性支气管炎患者和 22 例健康受试者的支气管肺泡灌洗液(BAL)和血清中的 SP-A 组成和功能。探讨了 SP-A 凝集能力与受试者疾病严重程度的关系。

结果

SP-A 存在 7 种主要的寡聚形式,大多数 SP-A 以复杂的寡聚形式存在。在凝集能力方面,更复杂的寡聚形式与更好的 SP-A 功能相关。这些形式在 BAL 中比在血清中更常见,但在疾病组之间没有差异。在 CF 患者中,更复杂的 SP-A 形式与更好的肺功能相关。

结论

SP-A 的组织结构影响其功能活性,并与 CF 中的疾病严重程度相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9078/3517609/568768a9e7e0/pone.0051050.g001.jpg

相似文献

1
Surfactant protein a in cystic fibrosis: supratrimeric structure and pulmonary outcome.
PLoS One. 2012;7(12):e51050. doi: 10.1371/journal.pone.0051050. Epub 2012 Dec 7.
2
Assessment of surfactant protein A (SP-A) dependent agglutination.
BMC Pulm Med. 2010 Nov 22;10:59. doi: 10.1186/1471-2466-10-59.
3
Functional heterogeneity of pulmonary surfactant protein-D in cystic fibrosis.
Biochim Biophys Acta. 2013 Dec;1832(12):2391-400. doi: 10.1016/j.bbadis.2013.10.002. Epub 2013 Oct 9.
5
Bronchoalveolar lavage fluid surfactant protein-A and surfactant protein-D are inversely related to inflammation in early cystic fibrosis.
Am J Respir Crit Care Med. 2003 Sep 15;168(6):685-91. doi: 10.1164/rccm.200301-005OC. Epub 2003 Jun 26.
6
Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis.
Eur Respir J. 2001 Apr;17(4):716-22. doi: 10.1183/09031936.01.17407160.
9
Pulmonary surfactant, lung function, and endobronchial inflammation in cystic fibrosis.
Am J Respir Crit Care Med. 2004 Nov 1;170(9):1000-5. doi: 10.1164/rccm.200405-575OC. Epub 2004 Jul 21.

引用本文的文献

1
Genetic Association With Acquisition in Cystic Fibrosis: Influence of Surfactant Protein D and Mannose-Binding Lectin.
Front Immunol. 2021 Feb 19;12:587313. doi: 10.3389/fimmu.2021.587313. eCollection 2021.
2
Genetic Association of Pulmonary Surfactant Protein Genes, SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD With Cystic Fibrosis.
Front Immunol. 2018 Oct 2;9:2256. doi: 10.3389/fimmu.2018.02256. eCollection 2018.
3
Surfactant protein A down-regulates epidermal growth factor receptor by mechanisms different from those of surfactant protein D.
J Biol Chem. 2017 Nov 10;292(45):18565-18576. doi: 10.1074/jbc.M117.800771. Epub 2017 Sep 27.

本文引用的文献

1
Assessment of surfactant protein A (SP-A) dependent agglutination.
BMC Pulm Med. 2010 Nov 22;10:59. doi: 10.1186/1471-2466-10-59.
2
Genetic complexity of the human innate host defense molecules, surfactant protein A1 (SP-A1) and SP-A2--impact on function.
Crit Rev Eukaryot Gene Expr. 2009;19(2):125-37. doi: 10.1615/critreveukargeneexpr.v19.i2.30.
4
Inhibition of airway proteases in cystic fibrosis lung disease.
Eur Respir J. 2008 Sep;32(3):783-95. doi: 10.1183/09031936.00146807.
6
Surfactant protein A--from genes to human lung diseases.
Curr Med Chem. 2006;13(27):3239-52. doi: 10.2174/092986706778773112.
8
alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients.
Eur Respir J. 2007 Feb;29(2):240-50. doi: 10.1183/09031936.00047306. Epub 2006 Oct 18.
9
Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data.
Am J Respir Crit Care Med. 2006 Oct 1;174(7):780-6. doi: 10.1164/rccm.200512-1919OC. Epub 2006 Jul 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验